leisure time -WSS

leisure time

author：hotspot 2025-09-06 03:50:40 - browse：82

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Continuity nursing helped my family in our darkest PICU moments

WSS

Hepatitis C has a cure — but many Americans still lack access to it

Readers discuss the intersection of pregnancy and addiction

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Stephen Quake on the Chan Zuckerberg quest to conquer disease

State Dept. review finds Biden bears some blame for Afghanistan failures

hotspot

leisure time

leisure time

Moonlake's readout produced a cash windfall. Risks remain

'Essentially witchcraft:' A former naturopath takes on the field

In age of alternative facts, a scholarly course on calling out crap

5 takeaways from STAT's examination of Zynex Medical

Alkermes shareholders re

Bright Health sells Medicare Advantage business to Molina

The cancer drug shortage isn’t new — and neither are the solutions

Hollywood unions extend contract negotiations for actors

In age of alternative facts, a scholarly course on calling out crap

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Wikipedia

Medicare details structure of new drug price negotiation program

Medical device trials still don't enroll enough women, study finds

Teladoc has a new CEO, but challenges remain the same

Duchenne breakthrough therapy leaves behind pioneering families

How one medical school became remarkably diverse

United colonoscopy coverage change 'may cost lives,' doctors say

explore

hotspot

hotspot

knowledge